Search results (59)
« Back to NewsFirst vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)
18 September 2023
COVID-19 Methods Public Engagement Research
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
First in-human trials commence for CCHF vaccine
13 September 2023
COVID-19 Methods Public Engagement Research
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
University of Oxford partners with CEPI to counter the threat of future pandemics
30 August 2023
COVID-19 Department Public Engagement Research
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
Director of Global Operations at OVG recognised in the King’s Birthday Honours 2023
22 June 2023
Awards & Appointments COVID-19
Dr Parvinder Aley, Director of Global Operations at the Oxford Vaccine Group, has been recognised and celebrated in the 2023 King’s Birthday Honours list. Dr Aley has been appointed an Officer of the Order of the British Empire (OBE) for services to vaccination during the COVID-19 pandemic.
Britain’s Covid research led the world – why have our clinical trials fallen off a cliff?
27 April 2023
Pressures on the NHS, a lack of doctors and post-Brexit delays are hampering our ability to develop cutting-edge drugs.
From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford
7 December 2022
Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed
It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard
13 September 2022
A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees
Novel all-in-one vaccine developed to tackle future coronavirus threats
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds
26 May 2022
Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study
16 May 2022
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
Oxford to work with Brazil to establish clinical research hub
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
One billion doses: A moment to celebrate but not a time to be complacent
30 July 2021
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.
Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope
30 July 2021
If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.
Oxford vaccine reaches one billion doses released
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
Oxford Vaccine Group among winners at NHS Parliamentary awards
9 July 2021
Awards & Appointments COVID-19
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
First trial participants vaccinated with Oxford COVID-19 variant vaccine
28 June 2021
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19
28 June 2021
Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study
21 June 2021
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.